Gera Neufeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gera Neufeld has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Ofra Kessler
Cancer Research Center, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
24 shared publicationsHai-Feng Zhang
11 shared publicationsHai-Ying Zou
11 shared publicationsJi-Wei Jiao
11 shared publicationsJian-Yi Wu
11 shared publicationsJuan-Juan Wang
11 shared publications
Latest Publications
- Open Access
Plexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity
Plexins are a family of nine single-pass transmembrane receptors with a conserved GTPase activating protein (GAP) domain. The plexin family is divided into four subfamilies: Type-A, type-B, type-C, and type-D plexins. Plexins function as receptors for axon guidance factors of the semaphorin family. The semaphorin gene family contains 22 genes that are divided into eight subclasses of which subclasses three to seven represent vertebrate semaphorins. The plexins and their semaphorin ligands have important roles as regulators of angiogenesis, cancer proliferation, and metastasis. Class 3 semaphorins, with the exception of sema3E, are the only semaphorins that do not bind directly to plexins. In order to transduce their signals, they bind instead to complexes consisting of receptors of the neuropilin family and various plexins. Some plexins also form complexes with tyrosine-kinase receptors such as the epidermal growth factor receptor ErbB2, the mesenchymal epithelial transition factor receptor (MET), and the Vascular endothelial growth factor receptor 2 (VEGFR2) and, as a result, can modulate cell proliferation and tumor progression. This review focuses on the roles of the different plexins in the control of cancer cell proliferation and invasiveness. Plexins also affect tumor progression and tumor metastasis by indirect mechanisms, such as modulation of angiogenesis and immune responses. However, these topics are not covered in the present review.
Open AccessPlexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity
Plexins are a family of nine single-pass transmembrane receptors with a conserved GTPase activating protein (GAP) domain. The plexin family is divided into four subfamilies: Type-A, type-B, type-C, and type-D plexins. Plexins function as receptors for axon guidance factors of the semaphorin family. The semaphorin gene family contains 22 genes that are divided into eight subclasses of which subclasses three to seven represent vertebrate semaphorins. The plexins and their semaphorin ligands have important roles as regulators of angiogenesis, cancer proliferation, and metastasis. Class 3 semaphorins, with the exception of sema3E, are the only semaphorins that do not bind directly to plexins. In order to transduce their signals, they bind instead to complexes consisting of receptors of the neuropilin family and various plexins. Some plexins also form complexes with tyrosine-kinase receptors such as the epidermal growth factor receptor ErbB2, the mesenchymal epithelial transition factor receptor (MET), and the Vascular endothelial growth factor receptor 2 (VEGFR2) and, as a result, can modulate cell proliferation and tumor progression. This review focuses on the roles of the different plexins in the control of cancer cell proliferation and invasiveness. Plexins also affect tumor progression and tumor metastasis by indirect mechanisms, such as modulation of angiogenesis and immune responses. However, these topics are not covered in the present review.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Table S1-S4. Table S1. Correlation between expression of LOXL2 or its spliced isoform L2Δ13 and clinicopathological characteristics in ESCC patients of cohort 1 (n = 252). Table S2. Patient demographics and clinical characteristics for tissue microarray cohort 2 in ESCC (n = 135). Table S3. Multivariate Cox regression for overall survival and disease-free survival of ESCC patients (n = 252). Table S4. Interacting proteins associated with LOXL2 and L2Δ13 in KYSE150 ESCC cells identified by high-performance liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) analysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Table S1-S4. Table S1. Correlation between expression of LOXL2 or its spliced isoform L2Δ13 and clinicopathological characteristics in ESCC patients of cohort 1 (n = 252). Table S2. Patient demographics and clinical characteristics for tissue microarray cohort 2 in ESCC (n = 135). Table S3. Multivariate Cox regression for overall survival and disease-free survival of ESCC patients (n = 252). Table S4. Interacting proteins associated with LOXL2 and L2Δ13 in KYSE150 ESCC cells identified by high-performance liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) analysis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Lysyl oxidase-like 2 (LOXL2), a copper-dependent enzyme of the lysyl oxidase family and its nonsecreted, catalytically dead spliced isoform L2Δ13, enhance cell migration and invasion, stimulate filopodia formation, modulate the expression of cytoskeletal genes, and promote tumor development and metastasis in vivo. We previously showed that LOXL2 reorganizes the actin cytoskeleton in esophageal squamous cell carcinoma (ESCC) cells, however, the underlying molecular mechanisms were not identified. Here, using interactome analysis, we identified ezrin (EZR), fascin (FSCN1), heat shock protein beta-1 (HSPB1), and tropomodulin-3 (TMOD3) as actin-binding proteins that associate with cytoplasmic LOXL2, as well as with its L2Δ13 variant. High levels of LOXL2 and L2Δ13 and their cytoskeletal partners correlated with poor clinical outcome in patients with ESCC. To better understand the significance of these interactions, we focused on the interaction of LOXL2 with ezrin. Phosphorylation of ezrin at T567 was greatly reduced following depletion of LOXL2 and was enhanced following LOXL2/L2Δ13 reexpression. Furthermore, LOXL2 depletion inhibited the ability of ezrin to promote tumor progression. These results suggest that LOXL2-induced ezrin phosphorylation, which also requires PKCα, is critical for LOXL2-induced cytoskeletal reorganization that subsequently promotes tumor cell invasion and metastasis in ESCC. In summary, we have characterized a novel molecular mechanism that mediates, in part, the protumorigenic activity of LOXL2. These findings may enable the future development of therapeutic agents targeting cytoplasmic LOXL2.Significance:LOXL2 and its spliced isoform L2Δ13 promote cytoskeletal reorganization and invasion of esophageal cancer cells by interacting with cytoplasmic actin-binding proteins such as ezrin.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Lysyl oxidase-like 2 (LOXL2), a copper-dependent enzyme of the lysyl oxidase family and its nonsecreted, catalytically dead spliced isoform L2Δ13, enhance cell migration and invasion, stimulate filopodia formation, modulate the expression of cytoskeletal genes, and promote tumor development and metastasis in vivo. We previously showed that LOXL2 reorganizes the actin cytoskeleton in esophageal squamous cell carcinoma (ESCC) cells, however, the underlying molecular mechanisms were not identified. Here, using interactome analysis, we identified ezrin (EZR), fascin (FSCN1), heat shock protein beta-1 (HSPB1), and tropomodulin-3 (TMOD3) as actin-binding proteins that associate with cytoplasmic LOXL2, as well as with its L2Δ13 variant. High levels of LOXL2 and L2Δ13 and their cytoskeletal partners correlated with poor clinical outcome in patients with ESCC. To better understand the significance of these interactions, we focused on the interaction of LOXL2 with ezrin. Phosphorylation of ezrin at T567 was greatly reduced following depletion of LOXL2 and was enhanced following LOXL2/L2Δ13 reexpression. Furthermore, LOXL2 depletion inhibited the ability of ezrin to promote tumor progression. These results suggest that LOXL2-induced ezrin phosphorylation, which also requires PKCα, is critical for LOXL2-induced cytoskeletal reorganization that subsequently promotes tumor cell invasion and metastasis in ESCC. In summary, we have characterized a novel molecular mechanism that mediates, in part, the protumorigenic activity of LOXL2. These findings may enable the future development of therapeutic agents targeting cytoplasmic LOXL2.Significance:LOXL2 and its spliced isoform L2Δ13 promote cytoskeletal reorganization and invasion of esophageal cancer cells by interacting with cytoplasmic actin-binding proteins such as ezrin.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Table S1-S4. Table S1. Correlation between expression of LOXL2 or its spliced isoform L2Δ13 and clinicopathological characteristics in ESCC patients of cohort 1 (n = 252). Table S2. Patient demographics and clinical characteristics for tissue microarray cohort 2 in ESCC (n = 135). Table S3. Multivariate Cox regression for overall survival and disease-free survival of ESCC patients (n = 252). Table S4. Interacting proteins associated with LOXL2 and L2Δ13 in KYSE150 ESCC cells identified by high-performance liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) analysis.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Table S1-S4. Table S1. Correlation between expression of LOXL2 or its spliced isoform L2Δ13 and clinicopathological characteristics in ESCC patients of cohort 1 (n = 252). Table S2. Patient demographics and clinical characteristics for tissue microarray cohort 2 in ESCC (n = 135). Table S3. Multivariate Cox regression for overall survival and disease-free survival of ESCC patients (n = 252). Table S4. Interacting proteins associated with LOXL2 and L2Δ13 in KYSE150 ESCC cells identified by high-performance liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) analysis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Figure S1-S9. Figure S1. Specificity of antibody directed against the L2Δ13 splice form of LOXL2 in histological analysis. Figure S2. LOXL2 and L2Δ13 promote ESCC cell migration and invasion. Figure S3. Histological analysis of tumors and popliteal lymph nodes derived from the xenografts. Figure S4. LOXL2 and L2Δ13 interact with actin-binding proteins ezrin, fascin, HSPB1 and TMOD3. Figure S5. Co-localizations of L2Δ13 with four cytoskeletal binding proteins in ESCC cells. Figure S6. Kaplan-Meier curves and log-rank tests of fascin, HSPB1 and TMOD3 for overall survival and disease-free survival in ESCC patients. Figure S7. Molecular models of LOXL2/L2Δ13 and its actin-binding interacting partners predict poor prognosis in ESCC patients. Figure S8. LOXL2 is an oncogenic modulator in the activation of ezrin via phosphorylating ezrin at T567. Figure S9. LOXL2 modulates PKC-stimulated ezrin-T567 phosphorylation in ESCC cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Figure S1-S9. Figure S1. Specificity of antibody directed against the L2Δ13 splice form of LOXL2 in histological analysis. Figure S2. LOXL2 and L2Δ13 promote ESCC cell migration and invasion. Figure S3. Histological analysis of tumors and popliteal lymph nodes derived from the xenografts. Figure S4. LOXL2 and L2Δ13 interact with actin-binding proteins ezrin, fascin, HSPB1 and TMOD3. Figure S5. Co-localizations of L2Δ13 with four cytoskeletal binding proteins in ESCC cells. Figure S6. Kaplan-Meier curves and log-rank tests of fascin, HSPB1 and TMOD3 for overall survival and disease-free survival in ESCC patients. Figure S7. Molecular models of LOXL2/L2Δ13 and its actin-binding interacting partners predict poor prognosis in ESCC patients. Figure S8. LOXL2 is an oncogenic modulator in the activation of ezrin via phosphorylating ezrin at T567. Figure S9. LOXL2 modulates PKC-stimulated ezrin-T567 phosphorylation in ESCC cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Lysyl oxidase-like 2 (LOXL2), a copper-dependent enzyme of the lysyl oxidase family and its nonsecreted, catalytically dead spliced isoform L2Δ13, enhance cell migration and invasion, stimulate filopodia formation, modulate the expression of cytoskeletal genes, and promote tumor development and metastasis in vivo. We previously showed that LOXL2 reorganizes the actin cytoskeleton in esophageal squamous cell carcinoma (ESCC) cells, however, the underlying molecular mechanisms were not identified. Here, using interactome analysis, we identified ezrin (EZR), fascin (FSCN1), heat shock protein beta-1 (HSPB1), and tropomodulin-3 (TMOD3) as actin-binding proteins that associate with cytoplasmic LOXL2, as well as with its L2Δ13 variant. High levels of LOXL2 and L2Δ13 and their cytoskeletal partners correlated with poor clinical outcome in patients with ESCC. To better understand the significance of these interactions, we focused on the interaction of LOXL2 with ezrin. Phosphorylation of ezrin at T567 was greatly reduced following depletion of LOXL2 and was enhanced following LOXL2/L2Δ13 reexpression. Furthermore, LOXL2 depletion inhibited the ability of ezrin to promote tumor progression. These results suggest that LOXL2-induced ezrin phosphorylation, which also requires PKCα, is critical for LOXL2-induced cytoskeletal reorganization that subsequently promotes tumor cell invasion and metastasis in ESCC. In summary, we have characterized a novel molecular mechanism that mediates, in part, the protumorigenic activity of LOXL2. These findings may enable the future development of therapeutic agents targeting cytoplasmic LOXL2.Significance:LOXL2 and its spliced isoform L2Δ13 promote cytoskeletal reorganization and invasion of esophageal cancer cells by interacting with cytoplasmic actin-binding proteins such as ezrin.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Lysyl oxidase-like 2 (LOXL2), a copper-dependent enzyme of the lysyl oxidase family and its nonsecreted, catalytically dead spliced isoform L2Δ13, enhance cell migration and invasion, stimulate filopodia formation, modulate the expression of cytoskeletal genes, and promote tumor development and metastasis in vivo. We previously showed that LOXL2 reorganizes the actin cytoskeleton in esophageal squamous cell carcinoma (ESCC) cells, however, the underlying molecular mechanisms were not identified. Here, using interactome analysis, we identified ezrin (EZR), fascin (FSCN1), heat shock protein beta-1 (HSPB1), and tropomodulin-3 (TMOD3) as actin-binding proteins that associate with cytoplasmic LOXL2, as well as with its L2Δ13 variant. High levels of LOXL2 and L2Δ13 and their cytoskeletal partners correlated with poor clinical outcome in patients with ESCC. To better understand the significance of these interactions, we focused on the interaction of LOXL2 with ezrin. Phosphorylation of ezrin at T567 was greatly reduced following depletion of LOXL2 and was enhanced following LOXL2/L2Δ13 reexpression. Furthermore, LOXL2 depletion inhibited the ability of ezrin to promote tumor progression. These results suggest that LOXL2-induced ezrin phosphorylation, which also requires PKCα, is critical for LOXL2-induced cytoskeletal reorganization that subsequently promotes tumor cell invasion and metastasis in ESCC. In summary, we have characterized a novel molecular mechanism that mediates, in part, the protumorigenic activity of LOXL2. These findings may enable the future development of therapeutic agents targeting cytoplasmic LOXL2.Significance:LOXL2 and its spliced isoform L2Δ13 promote cytoskeletal reorganization and invasion of esophageal cancer cells by interacting with cytoplasmic actin-binding proteins such as ezrin.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Figure S1-S9. Figure S1. Specificity of antibody directed against the L2Δ13 splice form of LOXL2 in histological analysis. Figure S2. LOXL2 and L2Δ13 promote ESCC cell migration and invasion. Figure S3. Histological analysis of tumors and popliteal lymph nodes derived from the xenografts. Figure S4. LOXL2 and L2Δ13 interact with actin-binding proteins ezrin, fascin, HSPB1 and TMOD3. Figure S5. Co-localizations of L2Δ13 with four cytoskeletal binding proteins in ESCC cells. Figure S6. Kaplan-Meier curves and log-rank tests of fascin, HSPB1 and TMOD3 for overall survival and disease-free survival in ESCC patients. Figure S7. Molecular models of LOXL2/L2Δ13 and its actin-binding interacting partners predict poor prognosis in ESCC patients. Figure S8. LOXL2 is an oncogenic modulator in the activation of ezrin via phosphorylating ezrin at T567. Figure S9. LOXL2 modulates PKC-stimulated ezrin-T567 phosphorylation in ESCC cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Figure S1-S9. Figure S1. Specificity of antibody directed against the L2Δ13 splice form of LOXL2 in histological analysis. Figure S2. LOXL2 and L2Δ13 promote ESCC cell migration and invasion. Figure S3. Histological analysis of tumors and popliteal lymph nodes derived from the xenografts. Figure S4. LOXL2 and L2Δ13 interact with actin-binding proteins ezrin, fascin, HSPB1 and TMOD3. Figure S5. Co-localizations of L2Δ13 with four cytoskeletal binding proteins in ESCC cells. Figure S6. Kaplan-Meier curves and log-rank tests of fascin, HSPB1 and TMOD3 for overall survival and disease-free survival in ESCC patients. Figure S7. Molecular models of LOXL2/L2Δ13 and its actin-binding interacting partners predict poor prognosis in ESCC patients. Figure S8. LOXL2 is an oncogenic modulator in the activation of ezrin via phosphorylating ezrin at T567. Figure S9. LOXL2 modulates PKC-stimulated ezrin-T567 phosphorylation in ESCC cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from LOXL2 Upregulates Phosphorylation of Ezrin to Promote Cytoskeletal Reorganization and Tumor Cell Invasion
Supplementary Materials and Methods